

# CUREator+

*Information Session Webinar*

*30<sup>th</sup> August 2023*

Funded by the Australian Government,  
Department of Health and Aged Care MRFF  
BioMedTech Incubator Program

CUREator+



BRANDON  
BIOCATALYST

# Acknowledgement of Country


*We acknowledge the Traditional Owners, the Wurundjeri and Boon Wurrung people of the Kulin Nation, on whose land we meet, share and work. We pay our respects to Elders past and present and extend our respect to Aboriginal and Torres Strait Islander people from all nations of this land.*

# Housekeeping

Welcome and housekeeping

Session recording

Q&A



**CUREator+** is a national program focused on accelerating the research translation and commercialisation of early-stage Australian medical research and medical innovations with commercial potential.

# About CUREator+

- CUREator+ will deliver the \$50 million MRFF BioMedTech Incubator program to support the commercialisation and translation of drugs, devices, diagnostics and digital technologies.
- The program is a partnership between Brandon BioCatalyst, managed by Brandon Capital, Australia's leading biomedtech investment firm; and ANDHealth, Australia's leading digital health organisation.
- CUREator+ brings together the experience of the Partners and their respective MRFF Early-Stage Translation and Commercialisation Support (ESTAC) programs, CUREator and ANDHealth+.

# The CUREator team

Australia's national biotech incubator

- Established in 2021, CUREator is a national biotech incubator delivered by Brandon BioCatalyst and backed by the MRFF and CSIRO.
- CUREator supports early-stage health and medical research and innovation in Australia through to proof-of-concept and beyond.
- The incubator supports life science companies and projects with:
  - Non-dilutive early-stage capital and support
  - Project de-risking to reach value inflection points
  - Commercially driven go/no-go decision gates
  - Access to commercial networks and expertise



**Patricia Rueda**  
Analyst

**Aaron DeBono**  
Analyst

**Amanda Vrselja**  
Program Head

# The ANDHealth team



Australia's leading digital health accelerator

- Established in 2017, ANDHealth supports Australian digital health companies to navigate the commercialisation pathway from ideation to institutional investment and international market entry through its highly specific programs.
- The flagship ANDHealth+ program provides commercialisation support from proven experts and non-dilutive funding to scale evidence-based digital health SMEs.
- To date the 20 companies in the ANDHealth+ program have delivered over 400 Jobs, raised \$148M in additional dilutive and non dilutive funding, secured over 1300 commercial customers, commenced 64 clinical trials and studies and served over 640,000 patients.



**Kim Smyth**  
GM of Investment



**Grace Lethlean**  
Chief Product Officer



**Amabel Tan**  
Director, TTRA &  
Lead, SaMD



**Max Streader**  
Portfolio Manager &  
Lead Analyst

# CUREator+ program overview

- CUREator+ will provide up to \$5 million of non-dilutive funding (per project) and support to Australian SMEs developing BioMedTech and digital health innovations towards improving patient health outcomes.
- Funding is available to support preclinical, clinical and/or commercial development of:
  - Therapeutics (novel or repurposed)
  - Diagnostics
  - Medical devices
  - Digital health technologies
- In general, innovations includes any intervention that prevents, monitors, manages, diagnoses or treats a disease state, its symptoms or risk factors.




# Accelerating commercialisation for early-stage life science companies



## Non-Dilutive Funding

Access up to \$5 million per project, delivered in tranches upon meeting commercial milestones.



## Commercial Capability Coaching

Commercial guidance, hands-on support, mentorship and access to a global network of proven experts.



## Investor-Relevant Endpoints

Project de-risking by linking funding to attainment of commercial milestones to attract follow on investment.

# Funding process

Funded by the Australian Government,  
Department of Health and Aged Care MRFF  
BioMedTech Incubator Program

CUREator+



BRANDON  
BIOCATALYST

# Funding rounds

CUREator+ will run two funding rounds: the first round is **currently open**, and the second funding round will open mid-2024.

To apply visit: <https://cureatorplus.grantplatform.com/>

## First funding round key dates:

Expressions of Interest (EOI) open:	17 August 2023 at 9:00am AEST
EOIs close:	6 October 2023 at 5:00pm AEDT
Outcomes from the EOI stage:	From late November 2023
Full applications from shortlisted applicants due:	From mid-January 2023
Successful applicants funded:	Q2 2024

# Round 1 Application process



## EOI applications

17th August – 6th October 2023

Interested applicants submit an online EOI for Stage 1 funding to CUREator+ for review by the CUREator+ Investment Review Committee.



## Full applications

From November

Shortlisted applicants prepare a full application and presentation that will be reviewed by the CUREator+ Investment Review Committee and the International Advisory Committee.



## Due diligence

Q1 2024

Shortlisted applicants will work with the CUREator team to complete corporate due diligence, IP review, project planning, timing, budgets and milestones.




## Round 1 announced

Q2 2024

Applicants that successfully complete due diligence will be endorsed for funding.

# Funding rounds and stages

CUREator+ will provide up to a maximum of \$5 million per project over two funding stages.



\*Note only Stage 1 companies will be invited to apply for Stage 2.

# Key eligibility criteria

- Any Australian SME defined as an Australian based for-profit company with less than 200 employees, or researcher(s) at an Australian university or research institute is eligible to apply for CUREator+ funding.
- The company or research team owns or has an exclusive right to Intellectual Property Rights relevant to the project proposal (exclusive rights to background intellectual property).
- Applicants must provide a letter of support from the Board (established company) or business development manager/tech transfer office for researcher applicants at Australian-based institutes and universities (New Company) where applicable.
- Project expenditure must be a direct cost of the project or be incurred by the company for required project audit activities.
- *Please refer to grant guidelines and our website for the full eligibility and funding criteria.*

# Project profile

Funded by the Australian Government,  
Department of Health and Aged Care MRFF  
BioMedTech Incubator Program

**CUREator+**



BRANDON  
**BIOCATALYST**

# CUREator+ project profile – Stage 1

**Funding available for Stage 1 is from \$1M and up to \$2.5M per project**

*Supports preclinical, clinical and commercial medical innovation projects based in Australia.*

## Project profile and activities

- A lead asset(s)/ product/ technology, which has demonstrated Proof of Concept / Principle.
- Should focus on critical path activities to improve the ability to commercialise, raise growth capital and/or execute on a market entry / growth strategy.
- Milestone based, tranche funding, with clearly defined "go/no-go".
- Access to matching capital, in-kind support will be viewed favourably.
- Demonstrate access to sufficient resources and management capability to complete the program.
- Project activities designed in consideration of third-party feedback, including industry, current or potential investors and/or partners validating the approach will be highly regarded.
- Proposed activities must be performed in Australia where possible.



# What are we looking for | Selection Considerations

Consideration will be given to:

- Uniqueness – the program will select novel, outstanding, maturing projects that address a significant unmet need and are competitively differentiated from existing standards of care and emerging products.
- Extent to which the product/solution delivers value through improved diagnosis, prevention, treatment, mitigation and/or management of chronic and acute conditions for the benefit of the patient.
- Clinical and commercial differentiation, IP position, market opportunity, maturity and development stage with the aim that CUREator+ funding will progress the opportunity to a clear de-risking value inflection point.
- Innovative science – what does the science/evidence-based data behind the project enable?
- Highly differentiated – how is this approach distinguished from existing solutions?
- Clear achievable project plan – a credible plan towards generating clinical and commercial outcomes including partnerships, commercial licensing, revenue, as appropriate.
- Strong team – diverse team with ability to deliver on the project.

# Additional information

To submit an application visit: <https://cureatorplus.grantplatform.com/>

Guidelines and additional information are available at:

- [www.brandonbiocatalyst.com/cureator/cureator-plus](http://www.brandonbiocatalyst.com/cureator/cureator-plus)
- [www.andhealth.com.au/our-programs/cureatorplus](http://www.andhealth.com.au/our-programs/cureatorplus)

30-minute meetings:

- To arrange a meeting to discuss any opportunities related to drugs, devices and diagnostics or general enquiries, please contact the CUREator team at: [info@cureator.com.au](mailto:info@cureator.com.au)
- To arrange a meeting to discuss any opportunity related to digital health and connected devices or general enquiries, please request a meeting here or contact the ANDHealth team at [cureatorplus@andhealth.com.au](mailto:cureatorplus@andhealth.com.au)

# Q&A

<https://cureatorplus.grantplatform.com/>

[info@cureator.com.au](mailto:info@cureator.com.au)

[cureatorplus@andhealth.com.au](mailto:cureatorplus@andhealth.com.au)